CAM
IBRX icon

CenterStar Asset Management’s ImmunityBio IBRX Stock Holding History

CenterStar Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,500
Closed -$82.2K – 529
2025
Q4 		$82.2K Buy
41,500
+10,300
+33% +$23.3K 0.02% 255
2025
Q3 		$76.8K Sell
31,200
-7,500
-19% -$19.3K 0.02% 276
2025
Q2 		$102K Buy
38,700
+18,200
+89% +$48.9K 0.02% 191
2025
Q1 		$61.7K Buy
+20,500
New +$62.1K 0.01% 323

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

CenterStar Asset Management's IBRX Position: Q1 2026 in Review

CenterStar Asset Management opened a new position in ImmunityBio (IBRX) in Q1 2026: 21,600 shares worth $165K. The stake represents 0.02% of the portfolio and ranks #451 among its holdings. This is a return to the name: CenterStar Asset Management previously reported a position in IBRX as recently as Q2 2025.

CenterStar Asset Management first reported a position in IBRX in Q1 2025 and has held it in 3 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • CenterStar Asset Management held 21,600 shares of ImmunityBio worth $165K as of Q1 2026.
  • ImmunityBio was a new CenterStar Asset Management position in Q1 2026.
  • ImmunityBio made up 0.02% of CenterStar Asset Management's portfolio in Q1 2026, its #451 holding.
  • CenterStar Asset Management first reported a position in ImmunityBio in Q1 2025 and has held it in 3 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on CenterStar Asset Management's 13F filing for Q1 2026, filed 1 May 2026.